Sign in
CompletedNo phase

The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD

Key facts

Who runs it
Shanghai Mental Health Center
Where
China7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
30 Jul 2021
Ended
29 Jan 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • deep brain stimulation
Record updated
6 July 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • aged 18-65 years old
  • a diagnosis of OCD based on The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5)
  • suffered from severe OCD symptoms over 5 years with substantial functional impairment
  • the Y-BOCS total score ≥ 25
  • met the criteria of treatment refractory. Treatment refractory is defined as failed 1) at least three adequate therapeutic trials of serotin reuptake inhibitors (SRIs), with clomipramine being one of the SRIs trials, 2) the use of at least two atypical antipsychotics as augmenting agents, 3) at least 12 sessions of therapist-guided cognitive-behavioral therapy while on a therapeutic dose of an SRIs. These patients have "failed" treatment by demonstrating <25% reduction of Y-BOCS scores or, despite >25% reduction in YBOCS score, by still experiencing significant impairment from their illness

Who cannot take part

  • a history of current or past diagnosis of any psychosis according to DSM-5 except for OCD
  • any clinical significant neurological disorder, traumatic brain injury, dementia, or medical illness
  • any contradiction of neurosurgery
  • any current or unstably remitted substance abuse or dependence
  • women who are pregnant or preparing for pregnant
  • severe suicide risk and tendency according to the investigators' judgements
  • participate in any other clinical trials within three months (except for registered studies)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The present study aims to explore the efficacy and safety of DBS targeted the combination of the anterior limb of internal capsule and nucleus accumbens (ALIC/NAcc-DBS) to refractory OCD, based on multicenter, randomized, double-blinded, sham-stimulation controlled design, that could help to obtain stronger evidence of the efficacy of multiple targets.

The 2 groups in the trial

  • DBS true-stimulation groupExisting treatment, for comparison

    The electrical stimulation will be 'turned-on' immediately after programming in true-stimulation group.

    Treatment: deep brain stimulation

  • DBS sham-stimulation groupSham treatment, for comparison

    The electrical stimulation will be 'turned-off' after programming in sham-stimulation group. The stimulation will begin until after completing three months of Y-BOCS and CGI assessments

    Treatment: deep brain stimulation

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Efficacy and Safety of Deep Brain Stimulation of Combined Anterior Limb of Internal Capsule and Nucleus Accumbens (ALIC/NAcc-DBS) for Treatment-refractory Obsessive-compulsive Disorder (OCD)
Record updated
6 July 2026